If they persist or worsen as your dose increases, it is essential to consult your healthcare provider for further guidance
For example, weight loss outcomes had to be weighed against tolerability: a 12 mg weekly dose produced the most dramatic reductions in body weight but also the highest rate of gastrointestinal complaints
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (Guidance Document PDF) FDA
Meta-analytic HR estimates across cardiovascular effectiveness outcomes We summarized the main results by presenting the meta-analytic HR estimates for the 2 primary effectiveness outcomes and 4 secondary outcomes comparing new users of dulaglutide, semaglutide, dapagliflozin, and empagliflozin (Figure 2) whenever estimates were available
No, SLU-PP-332 is a preclinical research compound, and there are currently no human safety or efficacy data available
And unlike other GLP-1s, it works on just one chemical pathway, which can be harder on the body and may increase side effects like nausea and GI distress, says Dr